DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers.
Saved in:
| Title: | DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. |
|---|---|
| Authors: | Huang TT; National Cancer Institute Bethesda United States., Nair JR; National Cancer Institute Bethesda, Maryland United States., Bowen C; National Cancer Institute Bethesda United States., Castro J; Accent Therapeutics (United States) Lexington, MA United States., Nousome D; National Institutes of Health Bethesda, Maryland United States., Nayak S; Accent Therapeutics (United States) Lexington, MA United States., Silver SJ; Accent Therapeutics (United States) Lexington, MA United States., Lee JM; National Cancer Institute BETHESDA, MD United States. |
| Source: | Molecular cancer therapeutics [Mol Cancer Ther] 2026 Mar 24. Date of Electronic Publication: 2026 Mar 24. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1538-8514 |
|---|---|
| DOI: | 10.1158/1535-7163.MCT-25-1196 |
